Study guide

10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia

Key Takeaways Explain This Topic AI

Pre-eclampsia is defined by new-onset hypertension (blood pressure >= 140/90 mmHg) presenting after 20 weeks of gestation combined with proteinuria (>= 300 mg/24h or PCR >= 30 mg/mmol) or maternal end-organ dysfunction (thrombocytopenia, renal insufficiency, impaired transaminases, pulmonary edema, or neurological disturbance).

Severe hypertension in pregnancy (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 110 mmHg) represents an obstetric hypertensive emergency requiring rapid blood pressure reduction within 30 to 60 minutes using intravenous labetalol, oral immediate-release nifedipine, or intravenous hydralazine to prevent maternal hemorrhagic stroke.

Magnesium sulfate is the definitive anticonvulsant for eclampsia resuscitation and pre-eclampsia seizure prophylaxis (Pritchard regimen: 4 g IV + 10 g IM loading, then 5 g IM q4h; Zuspan regimen: 4 g IV loading, 1 to 2 g/h IV maintenance); toxicity is monitored via patellar reflexes, respiratory rate, and hourly urine output, with intravenous calcium gluconate 10% serving as the immediate antidote.

HELLP syndrome is a microangiopathic hemolytic variant characterized by hemolysis (LDH > 600 IU/L, schistocytes), elevated transaminases (AST/ALT >= 2x ULN), and thrombocytopenia (< 100 x 10^9/L) carrying high risk of subcapsular hepatic hematoma rupture and disseminated intravascular coagulation.

Delivery of the fetus and placenta is the only definitive resolution for pre-eclampsia; delivery is indicated at >= 37 weeks in mild disease, at >= 34 weeks in severe pre-eclampsia (or immediately if uncorrectable maternal or fetal compromise), and immediately upon maternal stabilization in eclampsia.

Last updated: November 2026

Spectrum & Classification of Hypertensive Disorders in Pregnancy

Hypertensive disorders of pregnancy (HDP) complicate 5% to 10% of pregnancies worldwide and remain a leading cause of maternal and perinatal morbidity and mortality across the Caribbean. Pathophysiologically, pre-eclampsia stems from abnormal remodeling of maternal uterine spiral arteries: defective endovascular trophoblastic invasion prevents the conversion of narrow, high-resistance muscular spiral arteries into wide, low-resistance flaccid conduits. The resultant chronic placental ischemia stimulates the pathological release of anti-angiogenic factors into maternal circulation—predominantly soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng)—which neutralize circulating vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). The consequence is widespread maternal systemic endothelial cell dysfunction, microvascular vasospasm, and capillary hyperpermeability.

The International Society for the Study of Hypertension in Pregnancy (ISSHP) and ACOG classify hypertensive disorders into four distinct clinical categories:

Chronic Hypertension : Blood pressure >= 140 mmHg systolic and/or >= 90 mmHg diastolic predating pregnancy, diagnosed before 20 weeks of gestation, or persisting beyond 12 weeks postpartum.

Gestational Hypertension : New-onset hypertension (BP >= 140/90 mmHg on two readings at least 4 hours apart) developing at or after 20 weeks of gestation in the absence of proteinuria or systemic end-organ dysfunction. Blood pressure normalizes by 12 weeks postpartum.

Pre-eclampsia : New-onset hypertension presenting at or after 20 weeks of gestation combined with either proteinuria or new-onset maternal systemic end-organ dysfunction:

Proteinuria : Urinary protein excretion >= 300 mg per 24-hour urine collection, spot urinary protein-to-creatinine ratio (PCR) >= 30 mg/mmol (>= 0.3 mg/mg), or >= 2+ on automated dipstick testing if quantitative methods are unavailable.

Absence of Proteinuria : In the absence of proteinuria, pre-eclampsia is definitively diagnosed if new-onset hypertension is accompanied by any of the following features of systemic end-organ compromise.

Chronic Hypertension with Superimposed Pre-eclampsia : New proteinuria and/or maternal organ or uteroplacental dysfunction in a woman with chronic hypertension. A rise in previously controlled blood pressure warrants urgent assessment but does not establish superimposed pre-eclampsia by itself.

Pre-eclampsia with Severe Features

The presence of any of the following clinical or laboratory parameters categorizes the disease as pre-eclampsia with severe features , mandating immediate inpatient admission and aggressive medical stabilization:

Severe Hypertension : Systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 110 mmHg on two occasions at least 15 minutes apart while the patient is at rest.

Thrombocytopenia : Platelet count < 100 x 10^9/L.

Impaired Renal Function : Serum creatinine concentration > 97 to 100 mcmol/L (1.1 mg/dL) or a doubling of serum creatinine in the absence of other renal disease.

Impaired Hepatic Function : Serum transaminases (AST or ALT) elevated to greater than twice the upper limit of normal, or severe persistent right upper quadrant or epigastric pain unresponsive to analgesics and unassociated with other diagnoses.

Pulmonary Edema : Acute dyspnea, orthopnea, crackles on auscultation, and arterial desaturation.

New-Onset Neurological Symptoms : Persistent, throbbing frontal headache unresponsive to simple analgesics, visual disturbances (scotomata, photopsia, cortical blindness), altered mental status, or brisk hyperreflexia with clonus (>= 3 beats).

Eclampsia & HELLP Syndrome

Eclampsia : The occurrence of new-onset generalized tonic-clonic convulsions in a patient with pre-eclampsia that cannot be attributed to other neurological conditions (epilepsy, intracranial hemorrhage, encephalitis). Eclampsia may occur antepartum (38%), intrapartum (18%), or postpartum (44%, typically within the first 48 hours). It represents a cerebrovascular emergency caused by cerebral autoregulatory breakdown, microvascular endothelial leakage, and localized cerebral vasogenic edema (posterior reversible encephalopathy syndrome [PRES]).

HELLP Syndrome : A severe, life-threatening variant of pre-eclampsia characterized by microangiopathic hemolytic anemia, hepatic necrosis, and profound consumption of platelets. Diagnostic criteria include:

Hemolysis (H) : Microangiopathic blood smear demonstrating fragmented red blood cells (schistocytes, burr cells), elevated serum lactate dehydrogenase (LDH > 600 IU/L), elevated total bilirubin (>= 20.5 mcmol/L [1.2 mg/dL]), and low haptoglobin.

Elevated Liver Enzymes (EL) : Serum AST or ALT >= 70 IU/L or twice the upper limit of normal.

Low Platelets (LP) : Platelet count < 100 x 10^9/L.

HELLP syndrome carries high risks of subcapsular hepatic hematoma formation and rupture (manifesting with sudden excruciating right upper quadrant pain radiating to the right shoulder, peritoneal irritation, and hypovolemic shock), acute kidney injury, and disseminated intravascular coagulation (DIC).

Pharmacotherapy for Acute Severe Hypertension

Severe acute hypertension in pregnancy (systolic BP >= 160 mmHg or diastolic BP >= 110 mmHg) constitutes an obstetric emergency requiring prompt pharmacological intervention within 30 to 60 minutes. The overriding clinical objective is to lower blood pressure into a safe therapeutic window— target systolic 135 to 145 mmHg and diastolic 85 to 95 mmHg —to protect the maternal cerebral circulation from hemorrhagic stroke while preserving adequate uteroplacental perfusion. Overly aggressive, precipitous reduction of blood pressure is avoided because it compromises placental blood flow and precipitates acute fetal distress.

First-Line Emergency Antihypertensive Agents

Intravenous Labetalol : Combined competitive alpha-1 and non-selective beta-adrenergic blocker that decreases systemic vascular resistance without producing reflex tachycardia.

Dosing Protocol : Initial bolus of 20 mg IV over 2 minutes. If severe hypertension persists after 10 to 20 minutes, administer 40 mg IV, then 80 mg every 10 to 20 minutes to a maximum cumulative dose of 220 to 300 mg; alternatively, maintain via continuous infusion (1 to 2 mg/min).

Contraindications : Moderate-to-severe bronchial asthma, severe sinus bradycardia (heart rate < 60 bpm), second- or third-degree heart block, or overt decompensated heart failure.

Oral Immediate-Release Nifedipine : Dihydropyridine calcium channel blocker promoting peripheral arteriolar smooth muscle relaxation.

Dosing Protocol : 10 to 20 mg orally swallowed whole with water (never bitten or administered sublingually, as sublingual absorption produces uncontrolled, precipitous maternal hypotension and secondary fetal distress). Repeat 10 to 20 mg in 20 to 30 minutes if BP remains above threshold, followed by 10 to 20 mg every 4 to 6 hours as needed (maximum cumulative daily dose 180 mg).

Side Effects : Maternal reflex tachycardia, peripheral flushing, headache.

Intravenous Hydralazine : Direct arteriolar vasodilator.

Dosing Protocol : 5 to 10 mg IV slowly over 2 minutes. If blood pressure remains severe after 20 to 30 minutes, administer a second dose of 5 to 10 mg (maximum cumulative dose 20 to 30 mg).

Side Effects : Maternal hypotension, profound reflex tachycardia, nausea, headache, and fetal decelerations.

Maintenance Antihypertensives & Absolute Contraindications

For non-emergent maintenance control of chronic or gestational hypertension, first-line oral agents include oral Labetalol (100 to 400 mg two to three times daily), extended-release Nifedipine (30 to 90 mg once daily), and Methyldopa (centrally acting alpha-2 adrenergic agonist, 250 to 500 mg two to three times daily).

Absolute Pharmacological Contraindications : Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., enalapril, lisinopril) and Angiotensin Receptor Blockers (ARBs, e.g., losartan) are strictly contraindicated throughout pregnancy . Exposure in the second and third trimesters produces severe fetopathy: impaired fetal renal perfusion, renal tubular dysgenesis, anuria, profound oligohydramnios, secondary fetal pulmonary hypoplasia, intrauterine growth restriction, calvarial hypoplasia, and neonatal renal failure (Potter sequence).

Magnesium Sulfate Protocols & Toxicity Monitoring

Magnesium sulfate (MgSO4) is the undisputed international drug of choice for the prevention and treatment of eclamptic seizures, demonstrated to be vastly superior to diazepam and phenytoin in both the landmark Collaborative Eclampsia Trial and the Magpie Trial. Magnesium acts as a central N-methyl-D-aspartate (NMDA) receptor antagonist, blocks calcium channels, stabilizes excitable neuronal membranes, induces cerebral vasodilation, and decreases acetylcholine release at the motor endplate.

Clinical Regimens

Pritchard Regimen (Intravenous + Intramuscular Combination) : Extensively utilized in regional Caribbean hospitals and district facilities where automated infusion pumps are limited:

Loading Dose : 4 g IV as a 20% solution administered slowly over 5 to 15 minutes, accompanied immediately by 10 g IM (5 g deep IM into each upper outer quadrant of the buttock as a 50% solution, mixed with 1 mL of 1% lidocaine to minimize local pain).

Maintenance Dose : 5 g IM (50% solution) every 4 hours into alternating buttocks for 24 hours postpartum or 24 hours following the last seizure.

Zuspan Regimen (Intravenous Infusion) :

Loading Dose : 4 g IV in 100 mL 0.9% normal saline over 15 to 20 minutes.

Maintenance Dose : Continuous intravenous infusion of 1 to 2 g/hour via a dedicated infusion pump for 24 hours postpartum or 24 hours after the last convulsion.

Recurrent Seizure Management : If an eclamptic convulsion recurs while the patient is receiving maintenance magnesium sulfate, an additional intravenous bolus of 2 g MgSO4 is administered over 5 minutes.

Toxicity Monitoring & Antidote Administration

Because magnesium is eliminated almost exclusively by maternal renal excretion, impaired renal function rapidly produces life-threatening hypermagnesemia. Prior to administering each intramuscular dose or every hour during continuous intravenous infusion, the following three clinical parameters must be strictly confirmed:

Deep Tendon (Patellar) Reflexes : Must be present. Loss of the patellar reflex is the earliest and most sensitive clinical sign of magnesium toxicity , manifesting at serum levels of 4.0 to 5.0 mmol/L (8 to 10 mEq/L; therapeutic level is 2.0 to 3.5 mmol/L [4 to 7 mEq/L]).

Respiratory Rate : Must be >= 12 breaths per minute. Respiratory depression and central apnea occur at serum concentrations exceeding 5.0 to 6.0 mmol/L (10 to 12 mEq/L).

Hourly Urinary Output : Must exceed 30 mL/hour (or >= 100 mL over 4 hours). If urine output falls below 30 mL/h, magnesium administration must be withheld or the infusion rate halved, with urgent serum magnesium testing.

If patellar reflexes are lost, respiratory depression occurs, or cardiac conduction abnormalities emerge:

Step 1 : Discontinue magnesium sulfate immediately.

Step 2 : Administer 10 mL of 10% Calcium Gluconate (1 g) intravenously slowly over 3 to 5 minutes. Calcium competitively antagonizes magnesium at the neuromuscular junction.

Step 3 : Support maternal ventilation with 100% supplemental oxygen via bag-valve-mask or endotracheal intubation if respiratory arrest supervenes.

Delivery Timing & Obstetric Stabilization

Delivery of the fetus and placenta is the sole definitive cure for pre-eclampsia. Timing of delivery balances maternal safety against neonatal risks of iatrogenic prematurity:

Pre-eclampsia Without Severe Features : Deliver at 37+0 weeks of gestation (or upon reaching 37 weeks).

Pre-eclampsia With Severe Features >= 34+0 Weeks : Deliver promptly once maternal hemodynamics are stabilized with antihypertensives and magnesium sulfate.

Pre-eclampsia With Severe Features at 24+0 to 33+6 Weeks : In a specialized tertiary center with neonatal intensive care capabilities, expectant management can be considered for 24 to 48 hours to complete a course of antenatal corticosteroids (Betamethasone 12 mg IM two doses 24 hours apart, or Dexamethasone 6 mg IM four doses 12 hours apart) for fetal lung maturity and magnesium sulfate for fetal neuroprotection (< 32 weeks), provided maternal and fetal status remain stable.

Mandatory Immediate Delivery (Regardless of Gestational Age) : Eclampsia, pulmonary edema, disseminated intravascular coagulation, refractory severe hypertension despite multi-agent pharmacotherapy, progressive renal failure, suspected placental abruption, or non-reassuring fetal status.

Emergency Management of Eclamptic Seizures

When an eclamptic convulsion occurs, the clinical priority is maternal resuscitation:

Call for Help : Activate the multidisciplinary emergency obstetric response team.

Airway & Breathing : Place the patient in the left lateral tilt position to prevent aspiration and alleviate aortocaval compression. Clear the oropharynx, maintain an open airway, and administer 100% high-flow oxygen via a non-rebreather mask.

Control Seizures : Administer magnesium sulfate 4 g IV loading dose over 5 to 15 minutes.

Control Severe Blood Pressure : Administer IV labetalol or oral nifedipine once the convulsion ceases to bring blood pressure into the safe range.

Fetal Assessment : Transient fetal heart rate deceleration and loss of variability typically occur during and immediately following an eclamptic seizure. This represents maternal hypoxia and uterine vasoconstriction rather than irreversible fetal compromise. The clinician must avoid rushing into an emergency cesarean section during the active convulsion ; resuscitation of the mother almost invariably results in fetal heart rate recovery within 5 to 10 minutes.

Plan Delivery : Once the mother is stable and alert, proceed with delivery. Choose induction or cesarean according to gestational age, cervical findings, urgency and maternal/fetal condition; eclampsia alone does not mandate cesarean delivery.

Diagnostic Criteria & Clinical Management of Hypertensive Disorders in Pregnancy

Condition Onset & Diagnostic Criteria Hallmark Laboratory / Organ Signs Pharmacological & Obstetric Management

Gestational Hypertension New BP >= 140/90 after 20 weeks; no proteinuria None; normal platelets, renal & liver function Oral labetalol or nifedipine if BP >= 140/90; deliver at 37+0 weeks

Pre-eclampsia (Without Severe Features) BP >= 140/90 after 20 weeks PLUS proteinuria Proteinuria >= 300 mg/24h or PCR >= 30 mg/mmol Close outpatient/inpatient surveillance; deliver at 37+0 weeks

Pre-eclampsia with Severe Features BP >= 160/110 OR end-organ dysfunction after 20w Platelets < 100 x 10^9/L; Cr > 97 mcmol/L; AST/ALT >= 2x; headache/scotomata IV labetalol / oral nifedipine for BP >= 160/110; MgSO4 prophylaxis; deliver >= 34w

Eclampsia Generalized tonic-clonic seizures in pre-eclampsia Severe cerebral edema / microvascular spasm Airway, O2, left tilt; MgSO4 (4g IV + 10g IM); urgent delivery post-stabilization

HELLP Syndrome Microangiopathic hemolysis, hepatic necrosis, low platelets Schistocytes, LDH > 600, AST/ALT >= 70, Platelets < 100 x 10^9/L MgSO4, antihypertensives, blood products; deliver promptly once stabilized

Chronic Hypertension BP >= 140/90 prior to pregnancy or < 20 weeks Underlying essential or secondary renal/endocrine disease Discontinue ACEi/ARBs; transition to labetalol/nifedipine; deliver 37–39 weeks

Loading diagram... Emergency Resuscitation and Clinical Algorithm for Eclampsia